BUZZ – Lipocine shares soar after Canada approves its testosterone replacement therapy
路透社2026/10/07 12:56October 7 - ** Pharmaceutical company Lipocine (LPCN.O) saw its stock price rise 28% in pre-market trading to $2.7. ** Lipocine announced that (link) it has received approval from Health Canada for its oral testosterone replacement therapy drug, Tlando, for the treatment of male hypogonadism. ** In January 2024, Lipocine licensed the commercialization rights for Tlando in the US and Canada to the private company Verity Pharma. ** Lipocine is eligible to receive milestone payments of up to $259 million, as well as royalties ranging from 12% to 18% based on Tlando’s net sales. ** According to Lipocine, over 700,000 prescriptions for testosterone replacement therapy (TRT) are issued annually in Canada, with approximately 50% of patients reimbursed through private insurance. ** TRT is available in multiple formulations, including injections, oral medications, and topical gels. ** As of the previous trading session’s close, LPCN shares had declined by 73% year-to-date. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automatic translations may be inaccurate or lack desired context, Reuters does not guarantee the accuracy of translated content and provides such translations for user convenience only. Reuters accepts no responsibility for any harm or loss resulting from the use of automated translation features.)
October 7 - ** The pharmaceutical company Lipocine (LPCN.O) saw its share price rise 28% to $2.70 in pre-market trading
** LPCN stated (link) that it has received approval from Health Canada for its oral testosterone replacement therapy drug Tlando for the treatment of male hypogonadism
** In January 2024, Lipocine granted commercial rights to Tlando in the United States and Canada to the private company Verity Pharma
** Lipocine is eligible for milestone payments of up to $259 million, as well as royalties of 12% to 18% based on net sales of Tlando
** According to Lipocine, more than 700,000 testosterone replacement therapy (TRT) prescriptions are issued annually in Canada, with about 50% of patients reimbursed by private insurance
** TRT treatment is available in various forms, including injections, oral tablets, and topical creams
** As of the previous trading day's close, LPCN stock had fallen 73% year-to-date
(To assist non-English speakers, Reuters has automated its reports into several other languages. Because automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the automated text and provides it for readers’ convenience only. Reuters assumes no liability for any damage or loss caused by use of the automated translation service.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Michael Burry Calls Anthropic's Valuation a Bubble Worth 78 S&P 500 Companies
New Zealand Dollar moves sideways as US Dollar stabilizes amid rising bond yields
Fed Hike Odds Drop to 18%, Cuts at 0%: What a Hold Means for Bitcoin
RBC turns cautious on building products sector: fading expectations of housing recovery, multiple stocks downgraded
RBC Capital Markets has adopted a more cautious stance on the building products sector ahead of the third quarter earnings season, lowering earnings forecasts and downgrading several stocks. This is due to high interest rates, inflation, and weak housing demand, which may persist until 2027.
Crypto prices
More
